At a global level, the World Health Organization recommends G6PD testing prior to the administration of radical cure treatments for P. vivax malaria [14] However, among malaria-endemic countries, policies and practices related to G6PD testing and radical cure implementation vary significantly, based in part on the underlying epidemiology of G6PD deficiency as well as barriers to access and adoption [15]. Here, G6PD is linked to malaria.